Valuation : Dimerix Limited

Market Cap 174M 125M 108M 101M 92.55M 173M 11.84B 1.2B 466M 6.05B 470M 460M 19.49B P/E 2025
-24.3x
P/E 2026 -4.13x
Enterprise Value 158M 114M 97.94M 91.91M 84.09M 157M 10.76B 1.09B 423M 5.5B 427M 418M 17.71B EV / Sales 2025
49.4x
EV / Sales 2026 16.9x
Free-Float
77.77%
Yield 2025 *
-
Yield 2026 -
1 day-1.72%
1 week+3.64%
Current month+1.79%
1 month-1.72%
3 months+67.65%
6 months-27.85%
Current year-48.18%
1 week 0.26
Extreme 0.26
0.31
1 month 0.26
Extreme 0.26
0.33
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.06
Extreme 0.061
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 26/08/2018
Director of Finance/CFO 59 28/01/2026
Chief Tech/Sci/R&D Officer - 30/09/2023
Director TitleAgeSince
Director/Board Member 61 02/07/2015
Chairman - -
Director/Board Member - 26/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 Free

Chairman

100,000 0.0167%
12/12/25 Free

Chairman

100,000 0.0167%
12/12/25 Free

Director

100,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-1.72%+3.64%-40.62%+338.46% 125M
-1.58%-1.78%-0.83%+15.77% 50.35B
+0.78%-4.65%+430.22%+501.63% 45.2B
+2.95%+3.52%+47.12%+21.08% 44.71B
+0.25%-2.63%+7.86%+73.60% 41.24B
+0.43%-2.20%+14.55%+49.08% 33.08B
+1.43%+8.73% - - 17.81B
+0.06%-2.97%+23.31%+116.96% 16.56B
-0.14%+1.38%+16.85%+29.11% 14.82B
+0.54%-1.03%+80.71%+39.94% 14B
Average +0.19%-0.93%+64.35%+131.74% 27.79B
Weighted average by Cap. +0.33%-0.64%+92.57%+123.18%

Financials

2025 2026
Net sales 5.59M 4.02M 3.46M 3.25M 2.97M 5.54M 380M 38.4M 14.95M 194M 15.1M 14.77M 625M 6.35M 4.57M 3.93M 3.69M 3.38M 6.3M 432M 43.67M 17.01M 221M 17.17M 16.79M 711M
Net income -13.25M -9.54M -8.2M -7.7M -7.04M -13.15M -901M -91.08M -35.47M -461M -35.81M -35.03M -1.48B -29.81M -21.45M -18.46M -17.32M -15.85M -29.58M -2.03B -205M -79.8M -1.04B -80.56M -78.8M -3.34B
Net Debt -68.19M -49.07M -42.22M -39.62M -36.25M -67.65M -4.64B -469M -183M -2.37B -184M -180M -7.63B -15.92M -11.46M -9.86M -9.25M -8.46M -15.8M -1.08B -109M -42.62M -553M -43.02M -42.08M -1.78B
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
04/09/26 A$0.2850 -1.72% 2,999,082
01/09/26 A$0.2900 +3.57% 408,682
31/08/26 A$0.2800 +1.82% 1,368,829
28/08/26 A$0.2750 -5.17% 572,986
27/08/26 A$0.2900 0.00% 710,477